首页> 中文期刊> 《中外医疗》 >重组人脑利钠肽对于AMI心力衰竭患者循环内分泌的影响

重组人脑利钠肽对于AMI心力衰竭患者循环内分泌的影响

             

摘要

目的:探讨分析重组人脑利钠肽对于AMI心力衰竭患者循环内分泌的影响。方法整群选取该院2013年7月-2014年7月收治的68例AMI心力衰竭患者,将其分为观察组(34例)和对照组(34例),给予观察组患者常规治疗的基础上静脉注射重组人脑利钠肽。对比两组患者心力衰竭情况、LVEF、PRA、ALD和ATⅡ等指标。结果经治疗,两组LVEF均有心力衰竭缓解程度提高,其中观察组LVEF的提高优于治疗前和对照组,两组差异有统计学意义(P<0.05)。两组患者治疗前后的PRA、ALD、ATⅡ变化差异对比有意义(P<0.05),其中观察组整体下降程度优于对照组,两组差异有统计学意义(P<0.05)。结论对AMI心力衰竭患者运用重组人脑利钠肽有较高的临床治疗效果,改善患者心室功能,对患者的循环内分泌系统功能的恢复有着积极的促进作用,值得临床推广和应用。%Objective To investigate the effects of recombinant human brain natriuretic peptide on circular endocrine in patients with heart failure caused by AMI. Methods 68 cases of heart failure in patients with AMI admitted to our hospital in July 2013 to July 2014 year were selected and divided into observation group (34 cases) and control group (34 cases). Patients in observation group were given intravenous recombinant human brain natriuretic peptide treatment based on routine treatment. Indexes including heart failure, LVEF, PRA, ALD and AT II were compared between the two groups. Results After treatment, two groups of LVEF were relieved degree of heart failure increased, which improved better than the treatment observation group before LVEF and control group, compared two groups of significant differences (P<0.05). The two groups before and after treatment in patients with PRA, ALD, AT II changes in contrast differences significant (P<0.05), the overall decline in the degree of the observation group than the control group, compared two groups of significant differences (P<0.05). Conclusion The clinical treatment effect of AMI in patients with heart failure with recombinant human brain natriuretic peptide has higher, improve cardiac function in patients with, have positive effects on circulation function of patients with endocrine system recovery, is worthy of promotion and application.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号